Table 1.
Patient characteristics.
| All patients (n = 36) | Active cohort (n = 18) | Stable cohort (n = 18) | |
|---|---|---|---|
| Baseline characteristics | |||
| Age (mean, range) | 37 (22–54) | 36.1 (22–54) | 38.1 (24–49) |
| Female (%, number) | 81% (29/36) | 67% (12/18) | 94% (17/18) |
| Duration of MS (mean, range) | 10.8 (0–29) | 11.5 (1–29) | 10.2 (0–21) |
| Previously treated (%, number) | 97% (35/36) | 100% (18/18) | 94% (17/18) |
| ARR (mean) | 1.0 | 1.0 | 1.1 |
| EDSS (mean, range) | 2.7 (0–6.0) | 2.9 (1.0–5.5) | 2.4 (0–6.0) |
| Disease activity on FTY | |||
| Clinical relapse/s (%, number) | 28% (10/36) | 56% (10/18) | None |
| NEL (mean, range) | 5.5 (0–31) | 12 (1–31) | 0 (0–1) |
| ≥5 NEL (%, number) | 31% (11/18) | 61% (11/18) | None |
Baseline demographics and multiple sclerosis (MS) disease details (duration, previous treatment, 2-year annualized relapse rate (ARR) and expanded disability status score (EDSS)) are shown in the first part of the table. The proportion of patients developing one or more clinical relapses, the mean number of new or enlarging T2 MRI lesions (NEL), and the proportion of patients developing five or more NEL over the 24-month study period are shown in the second part of the table. Data are shown for all patients combined and for Active and Stable cohorts separately.